NCT05512104

Brief Summary

estimation of the clinical characters and out come of adult acute myeloid leukemia patients • correlation of the estimated clinical characters and outcome to the expression of CD200

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
51

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2022

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 16, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 23, 2022

Completed
9 days until next milestone

Study Start

First participant enrolled

September 1, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2023

Completed
Last Updated

August 23, 2022

Status Verified

August 1, 2022

Enrollment Period

10 months

First QC Date

August 16, 2022

Last Update Submit

August 20, 2022

Conditions

Acute Myeloid Leukemia

Outcome Measures

Primary Outcomes (1)

  • Prognosis of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression

    Prognostic value of CD200 and CD56 in acute myeloid leukemia

    1 year

Interventions

bone marrow aspirate and biopsyPROCEDURE

fiow cytometry of bone marrow aspirate

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

newly diagnosed Adult patients with AML, were treated with 3+7 protocol consists of 3 days doxorubicin (45mg/m2 ) and 7 days cytarabine (100-200 mg/m2 IV continuous infusion over 24 hours

You may qualify if:

  • newly diagnosed Adult patients with AML, were treated with 3+7 protocol consists of 3 days doxorubicin (45mg/m2 ) and 7 days cytarabine (100-200 mg/m2 IV continuous infusion over 24 hours

You may not qualify if:

  • Promyelocytic leukemia (M3)
  • Secondary acute myeloid leukemia
  • aml patients above the age of 60 yrs
  • aml patients with end organ failure
  • patient not candidate for (3+7)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Damiani D, Tiribelli M, Raspadori D, Sirianni S, Meneghel A, Cavalllin M, Michelutti A, Toffoletti E, Geromin A, Simeone E, Bocchia M, Fanin R. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors. Oncotarget. 2015 Oct 6;6(30):30212-21. doi: 10.18632/oncotarget.4901.

    PMID: 26338961BACKGROUND

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Interventions

Biopsy

Condition Hierarchy (Ancestors)

Leukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

CytodiagnosisCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisSpecimen HandlingDiagnostic Techniques, SurgicalSurgical Procedures, OperativeInvestigative Techniques

Central Study Contacts

asmaa gamal, master

CONTACT

01091076754asmaagamak2@gmail.com

mohamed ramadan, MD

CONTACT

01097510010

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant lecturer

Study Record Dates

First Submitted

August 16, 2022

First Posted

August 23, 2022

Study Start

September 1, 2022

Primary Completion

July 1, 2023

Study Completion

August 1, 2023

Last Updated

August 23, 2022

Record last verified: 2022-08